ESC Professional Premium Access

Development and validation of the ASGARD-S risk score for optimal timing of echocardiograms in asymptomatic patients with non-severe aortic valve stenosis: the SEAS and SALTIRE II trials

Congress Presentation

About the speaker

Doctor Edina Hadziselimovic

Bispebjerg University Hospital, Copenhagen (Denmark)
1 presentation
1 follower

7 more presentations in this session

Effect of Aficamten on Cardiac Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The SEQUOIA-HCM CMR Trial

Speaker: Doctor A. Masri (Portland, US)

Thumbnail

Effect of Aficamten on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM

Speaker: Doctor J. Spertus (Kansas City, US)

Thumbnail

Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Speaker: Doctor S. Hegde (Boston, US)

Thumbnail

Safety and Outcomes of Standard of Care Medications Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in FOREST-HCM Trial

Speaker: Doctor A. Masri (Portland, US)

Thumbnail

Aortic valve replacement versus conservative treatment in asymptomatic severe aortic stenosis

Speaker: Associate Professor M. Banovic (Belgrade, RS)

Thumbnail

Access the full session

Trial updates and other studies in hypertrophic cardiomyopathy and aortic stenosis

Speakers: Doctor E. Hadziselimovic, Doctor A. Masri, Doctor J. Spertus, Doctor S. Hegde, Doctor A. Masri...
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations